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IgEAbstract Background: Vitamin D plays a role in the pathogenesis of asthma as it has a potent
immunomodulatory effect acting on the cells of innate immunity. In asthmatic children low vitamin
D levels are associated with poor asthma control, reduced lung function, increased medication
intake, and exacerbations. Little is known about vitamin D in adult asthma patients or its associa-
tion with asthma control and inﬂammatory markers of asthma.
Objective: To establish the relationship between vitamin D serum levels, pulmonary function,
asthma control, IgE level and exhaled FENo.
Methods: This study comprised 55 subjects (15 healthy volunteers, 40 asthmatic patient) who
underwent history taking, HRCT, pulmonary function test, FENO, total serum IGE level and serum
25(OH)D3 level.
Results: Vitamin D deﬁciency and insufﬁciency were observed in uncontrolled asthmatic
patients. Patients with vitamin D deﬁciency and insufﬁciency had lower pulmonary function, higher
serum IgE level, FENO and higher number of exacerbations in the last year. Total serum IgE level,
FENO, and number of exacerbations showed a negative correlation with serum 25(OH) vitamin D.
Serum 25(OH)vitamin D showed a signiﬁcant positive correlation with pulmonary function in asth-
matic patients.
Conclusion: The lower the vitamin D level deﬁciency or insufﬁciency, the more the asthma
exacerbation, the less the asthma control, the higher the serum level of IgE and higher FENO.
Also low vitamin D associated with airway remodeling is presented by small airway affection
and HRCT ﬁndings.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Vitamin D is a seco-steroid hormone important in bone
mineralization and calcium homeostasis. Recently, research
has found that vitamin D may play a role in multiple chronic
diseases such as cancer, autoimmune diseases, infections, and
cardiovascular disorders [1,2].rculosis.
780 H.M.S. Samaha et al.Vitamin D may also have a role in several diseases involv-
ing the respiratory system. Higher vitamin D concentrations,
assessed by 25-hydroxyvitamin D [25(OH)D], have been asso-
ciated with better lung function as measured by forced expira-
tory volume in 1 s (FEV1) in a large cross-sectional study of
the U.S. population in the NHANES III [3].
Asthma represents one of the most common chronic dis-
eases and is a major public health problem worldwide. In the
majority of patients control of asthma as deﬁned by guide-
lines can be achieved with long-term maintenance med-
ications [4]. However, a substantial proportion of patients
do not achieve optimal asthma control despite even high
dose treatment. In particular inadequately controlled patients
with severe persistent asthma are at high risk of severe
exacerbations and asthma-related mortality. These patients
represent the greatest unmet medical need among the asth-
matic population today. Vitamin D insufﬁciency is increas-
ingly recognized in the general population, and has been
largely attributed to dietary, lifestyle and behavioral changes
[1,5]. While its musculoskeletal consequences are well estab-
lished, a new hypothesis links asthma to subnormal vitamin
D levels [6–8].
Vitamin D has several effects on the innate and adaptive
immune systems that might be relevant in the primary preven-
tion of asthma, in the protection against or reduction of
asthma morbidity, and in the modulation of the severity of
asthma exacerbations [9,10].
Cross-sectional data indicate that low 25(OH)D levels in
patients with mild to moderate asthma are correlated with
poor asthma control, reduced lung function, reduced glucocor-
ticoid response, more frequent exacerbations, and consequent
increased steroid use [11].
Therefore, the aim of this study was to prospectively inves-
tigate vitamin D insufﬁciency and deﬁciency in adult patients
with asthma and its potential relationship with markers of
asthma severity and control.Methods
A cross-sectional case-control study conducted on 55 subjects
‘‘15 healthy volunteers, 40 recruited from out patient’s clinic
diagnosed as asthma’’. Asthmatic patients included 15 male
and 25 female between October 2013 and September 2014, they
were diagnosed as controlled, partially controlled and uncon-
trolled asthmatic patients.
Asthma control was categorized as controlled, partly con-
trolled or uncontrolled in agreement with Global Initiative
for Asthma (GINA) guidelines [12]. In particular, levels of
asthma control were deﬁned depending on the presence/ab-
sence of day time symptoms, limitations of activities, nocturnal
symptoms/awakening, need for reliever/rescue treatment, and
FEV1 results.
Exclusion criteria
Smokers, patients using oral corticosteroid or receiving
immunosuppressive drugs, patients with chronic liver disease,
chronic renal failure, diabetic patient, abnormalities in thyroid
or other endocrinal abnormalities, past history of tuberculosis
or other connective tissue diseases, overt bone deformities and
patient receiving calcium or vitamin D supplements.All patients were subjected to a complete history taking
(age, sex, occupational exposure, asthma duration, current
asthma medication, number of acute attack/last year, family
history of allergy, phenotypic manifestation) and physical
examination. The following were done for each studied subject
in the same day: – high resolution CT (HRCT), pulmonary
function tests, Fractional exhaled nitric oxide (FENO).
Laboratory investigation: – Routine investigation included
complete blood picture, serum creatinine, liver enzymes, alka-
line phosphatase, serum calcium, phosphate. – Measurement
of serum total immunoglobulin E (IgE) level, and vitamin D
level.
HRCT of the chest: Determination of hyperinﬂation,
mosaic perfusion, tree in bud or central dilation. HRCT of
the chest was performed using a 64-row, multiple detector
CT scanner (Philips Company, etherland).
Pulmonary function test
Spirometry (BTL-08 spiro, Germany) was performed to deter-
mine the lung function measurements and bronchodilator
reversibility. Post-bronchodilator FEV1/FVC% and FEV1
were measured 15 min after inhalation of 400 lg salbutamol.
Fractional exhaled nitric oxide (FENO) was measured by the
NIOX system (BEDFONT SCIENTIFIC limited 2009) by use
of a single-breath on-line method according to European
Respiratory Society/American Thoracic Society guidelines
[13]. Brieﬂy, the subject inhaled NO-free air to total lung
capacity and exhaled through a dynamic ﬂow restrictor with
a target ﬂow of 50 mL/s for 10 s. No nose clip was used. The
NIOX system was calibrated according to the manufacturer’s
instructions. FENO (ppb) < 25 means airway inﬂammation
unlikely, FENO (ppb) 26–49 mild airway inﬂammation,
FENO (ppb) > 50 means signiﬁcant airway inﬂammation.
Measurement of serum vitamin D level [measured as 25-hy-
droxy cholecalciferol, 25(OH)D]wasmade in all subjects, using
chemiluminescent microparticle immunoassay ‘‘ARCHITECT
i1000SR-Abbott diagnostics; Abbott Laboratories, USA’’.
Normal level of vitamin D is deﬁned as a 25-OH Vitamin D
concentration greater than 30 ng/mL. Vitamin D insufﬁciency
is deﬁned as a 25-OH Vitamin D concentration of 20–30 ng/
mL. Vitamin D deﬁciency is deﬁned as a 25-OHVitamin D level
less than 20 ng/mL.
Serum level of Immunoglobulin E (total) was estimated using
chemiluminescent microparticle immunoassay ‘‘ARCHITECT
c4000 – Abbott diagnostics; Abbott Laboratories, USA’’ and
expressed as IU/L. It was determined as elevation if serum
T-IgE > 100 IU/L.
BMI is deﬁned as body weight divided by the square of their
height- with the value universally being given in units of kg/m2.Statistical analysis
All statistical analyses were performed using a statistical soft-
ware package (Statistics Package for the Social Sciences, SPSS
16.0, data are expressed as the mean ± SD (standard devia-
tion). Comparisons of continuous data among groups were
performed by the ANOVA test (for normal distribution) or
the Kruskal Wallis test (for abnormal distribution).
Categorical variables between different groups were analyzed
by the v2 test. Spearman Correlations were used for
Table 1 Characteristics of patients with asthma and healthy subjects.
GroupI
N= 15
healthy
GroupII
N= 13
Controlled
GroupIII
N= 12
Partiallycontrolled
GroupIV
N= 15
Uncontrolled
P value
Age 42 ± 10 38 ± 13 40 ± 12 41 ± 9 P> 0.05
Sex
Male 9(60%) 4(31%) 4(33%) 7(47%) P> 0.05
Female 6(40%) 9(69%) 8(67%) 8(53%)
Family history
Positive 0 (0%) 2 (15%) 4(33%) 9(60%) P< 0.01
Negative 15(100%) 11(85%) 8(67%) 6 (40%)
Other allergy
Positive 0 (0%) 5 (38%) 6 (50%) 6 (40%) P< 0.01
Negative 15(100%) 8 (62%) 6 (50%) 9 (60%)
Vitamin D
Suﬃcient 11(73%) 8 (62%) 3 (25%) 2 (13%) P< 0.001
Insuﬃcient 4 (27%) 5 (38%) 7 (58%) 7 (47%)
Deﬁcient 0 (0%) 0 (0%) 2 (17%) 6 (40%)
HRCT
Normal 15(100%) 10 (77%) 1(8%) 1 (7%) P< 0.001
Hyperinﬂation 0 (0%) 2 (15%) 6 (50%) 6 (40%)
Mosaic perfusion 0 (0%) 1 (8%) 1(8%) 3 (20%)
Central dilation 0 (0%) 0 (0%) 2 (17%) 4 (26%)
Tree inbud 0 (0%) 0(0%) 2 (17%) 1 (7%)
NO of acute attack/last year 0 0 (0–3) 1 (0–4) 7 (3–15) P< 0.01
FEV1% of predicted 94 ± 1.7 92 ± 5.5 79 ± 6.7 48 ± 10.4 P< 0.001
FEV1/FVC 92 ± 2.1 91 ± 5.1 80 ± 6.7 60 ± 13 P< 0.001
FEF25-75% 91 ± 3.9 76 ± 23 46 ± 16 30 ± 9.2 P< 0.001
IGE 25 (15–49) 52(20–100) 158(47–320) 298(59–500) P< 0.001
FENO 11 ± 4.2 19 ± 4.2 29 ± 5.1 41 ± 6.1 P< 0.001
Duration of asthma 0 12 ± 3.4 14 ± 5.9 15 ± 4.7 P> 0.05
BMI 24 ± 4.8 25 ± 3.3 22 ± 3.3 24.8 ± 3.3 P> 0.05
Vitamin D and asthma 781correlation analysis. P values less than 0.05 were considered as
statistically signiﬁcant.
Results
A total of 55 subjects comprising 40 asthmatic patients (15
male and 25 female) and 15 control (GroupI) were enrolled
in this study. The asthmatic patients were divided in 3 groups
according to the GINA guideline, group II included 13
controlled asthmatic patients, group III included 12 partially
controlled asthmatic patients and group IV included 15 uncon-
trolled asthmatic patients.
Table 1 showed there was no signiﬁcant difference between
studied groups as regards age, sex, duration of illness and
BMI. There was a signiﬁcant difference between studied
groups as regards family history of allergy, other allergic
manifestations and HRCT ﬁndings.
There was a highly signiﬁcant difference between studied
groups as regards FEV1% and FEF25–75% which was much
lower in uncontrolled asthmatics.
Vitamin D deﬁciency and insufﬁciency were observed in
uncontrolled asthmatic patients. IgE level and FENO were also
higher in uncontrolled asthmatic patients.
In Table 2 asthmatic patients were divided into 3 groups
according to serum level of 25(OH) vitamin D. Group A
included 9 patients (22%) with deﬁcient vitamin D, group B
included 19 (48%) asthmatic patients with insufﬁcient vitaminD and group C included 12 patients (30%) with sufﬁcient
serum level of vitamin D.
Patients with vitamin D deﬁciency and insufﬁciency had
lower pulmonary function, higher serum IgE level, FENO
and a higher number of exacerbations in the last year.
Tables 3 and 4 showed a signiﬁcant positive correlation
between serum 25(OH)vitamin D and pulmonary function
in asthmatic patients. While serum total IgE level, FENO,
and number of exacerbations showed a negative correlation
with serum 25(OH) vitamin D.
Discussion
Our study shows that there is a positive association between
vitamin D levels and asthma control as deﬁned by GINA
parameters. It is tempting to speculate that this correlation is
based on the effect that vitamin D has an immune function.
In fact, a number of studies have established that vitamin D
is a principal controller of innate immunity, with the produc-
tion of antimicrobial peptides able to kill viruses, bacteria
and fungi [14], and that it exerts an inhibitory effect on the
inﬂammatory response to viral infections [15].
There was a positive relationship between vitamin D status
(as reﬂected by serum 25(OH)D concentrations) and asthma
control. Lower 25(OH)D levels are associated with worse lung
function, higher levels of exhaled NO, higher serum IgE level,
and more changes in HRCT.
Table 2 Characterstics of asthmatic patients according to serum vit-D level.
Group A
Deﬁcient Vitamin D
N= 9 (22%)
Group B
Insuﬃcient Vitamin D
N= 19 (48%)
GroupC
Suﬃcient Vitamin D
N= 12 (30%)
P value
Age 35 ± 8.1 43 ± 9.4 35 ± 9.2 P> 0.05
Sex
Male 2 (22%) 9 (47%) 4 (33%) P> 0.05
Female 7 (78%) 10 (53%) 8 (67%)
Family history
Positive 3 (33%) 11 (58%) 1 (8%) P< 0.05
Negative 6 (67%) 8 (42%) 11 (82%)
Other allergy
Positive 2 (22%) 10 (53%) 5 (42%) P> 0.05
Negative 7 (78%) 9 (47%) 7 (58%)
BMI 25 ± 1.9 24 ± 3.3 23 ± 3.4 P> 0.05
No of acute attack/last year 6 (0–10) 8 (0–15) 2 (0–3) P< 0.05
Duration of asthma 13.3 ± 5.4 16.4 ± 7.3 9.9 ± 4.2 P< 0.05
HRCT
Normal 1 (11%) 5 (26%) 6 (50%) P> 0.05
Hyperinﬂation 4 (45%) 6 (32%) 4 (33%)
Mosaic perfusion 1 (11%) 2 (10.5%) 2 (17%)
Central dilation 2 (22%) 4 (21%) 0 (0%)
Tree inbud 1 (11%) 2 (10.5%) 0 (0%)
FEV1% of predicted 56 ± 18.1 70 ± 21.2 86 ± 10.9 P< 0.001
FEV1/FVC 60 ± 14.4 78.5 ± 15.4 85 ± 9.7 P< 0.001
FEF25-75% 40 ± 12 41 ± 19 71 ± 26 P< 0.001
IGE 158 (56–500) 168 (47–320) 56 (20–85) P< 0.001
FENO 47 ± 1.5 29 ± 1.9 19 ± 3.6 P< 0.001
Table 3 Correlation coefﬁcients between 25(OH) Vitamin D serum level to clinical and radiological investigated data in asthmatic
patients.
Age Sex Duration of
asthma
No of acute
attack/last year
Family history
of allergy
Other types
of allergy
BMI HRCT
R 0.005 0.2 0.43 0.53 0.03 0.1 0.17 0.49
P P> 0.05 P> 0.05 P< 0.001 P< 0.001 P< 0.01 P > 0.05 P> 0.05 P< 0.001
Table 4 Correlation coefﬁcients between 25(OH) Vitamin D
serum level to pulmonary function and laboratory investigated
data in asthmatic patients.
FEV1% FEV1/FVC FEF25-75% FENO IgE
R 0.54 0.49 0.54 0.70 0.65
P P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
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Abd ElAety et al. [17] who noted that; there was a positive cor-
relation between 25(OH)D levels and FEV1%.
The frequency of vitamin D insufﬁciency was highest in
patients with uncontrolled asthma: The ﬁndings of the present
study conﬁrm and extend in adult patients with various
degrees of asthma control in the previous reports in which vita-
min D status is associated with asthma severity and control in
children [18,19].
There was a strong association between serum level of
vitamin D and asthma duration and the number of acute
attacks, these ﬁndings are in agreement with recent studies
showing that insufﬁcient vitamin D status is associated with
an increase in the risk of asthma exacerbations in patients ofthe Childhood Asthma Management Program (CAMP) cohort
[20] and with augmented airway responsiveness and increased
risk of asthma hospitalization in children with asthma living in
Costa Rica [21].
Airway epithelia contain high levels of the enzyme that con-
verts circulating 25-OH-vitamin D3 to its active form, 1,25-
OH-vitamin D3. The active form of vitamin D has local effects
in response to respiratory infections and might dampen the
inﬂammation that is the consequence of these infections [22].
Reduced vitamin D levels are associated with increased expres-
sion of TNF-alpha, suggesting that enhanced expression of
this pro-inﬂammatory cytokine is a potential pathway by
which reduced vitamin D levels could exert pro-inﬂammatory
effects in asthma [23,24].
A study with bronchial biopsies demonstrated an inverse
association of vitamin D levels and airway smooth muscle
mass [18]. In vitro vitamin D inﬂuenced airway smooth mus-
cle remodeling by exerting an inhibitory effect on passively
sensitized airway smooth muscle growth and contractility
[25].
Our study showed patients with uncontrolled asthma have
features suggestive of airway remodeling like CT changes,
airﬂow limitation and small airway affection.
Vitamin D and asthma 783FeNO and serum level of IgE are mirrors of allergic eosino-
philic inﬂammation which reﬂect allergen exposure and multi-
ple sensitization.
In our study there is strong negative correlation between
FeNO and serum level of IgE and vitamin D status (as reﬂected
by serum 25(OH)D concentrations). Also asthmatic patients
with vitamin D deﬁciency or insufﬁciency had higher readings
of FeNO and serum level of IgE.
This could be explained that vitamin D had a role in inﬂam-
mation and allergic reaction. Further, recent data suggest that
vitamin D interacts with glucocorticoid signaling pathways in
ways that are clinically relevant, and that vitamin D may poten-
tially improve glucocorticoid responsiveness in severe asthmatics
by up-regulation of IL-10 production from CD4+ cells [26].
Further studies are needed to investigate the association
between vitamin D concentration with asthma control ‘‘ is this
is a consequence of life style, dietary changes or medication’’
and its relation to asthma mortality. Large follow up studies
are needed to study the effect of vitamin D supplementation
on airway remodeling and lung function.
Conclusion
The lower levels of vitamin D were associated with reduced
asthma control, the more reduced lung function, more expo-
sure to asthma exacerbation, more liability to airway remodel-
ing, and more allergic reactions.
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